Fig. 1 · Structure

Documents & Downloads

FTY720 (Fingolimod)

Cat. No. A10408 CAS 162359-56-0

S1P Receptor antagonist

FTY720 is a derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb Iscaria sinclarii as well as a structural analog of sphingosine.

In Stock

Publications for FTY720 (Fingolimod)

6 publications citing this product

  1. Tina Sepasi, .et al. , Int J Pharm, 2023, Apr 5;636:122815 PMID: 36907279
  2. Tina Sepasi, .et al. , BioImpacts, 2022, 28 May PMID: 37193076
  3. Zengzi Zhou, .et al. , Infect Immun, 2020, Oct 19;88(11):e00281-20 PMID: 32868341
  4. Mayu Idehara, .et al. , Traditional & Kampo Medicine, 2020, 22 July
  5. Luwa Yuan, .et al. , Sci Rep, 2019, 9:11156 PMID: 31371790
  6. Sakai Y, .et al. , Int J Biol Macromol, 2018, Nov 22;124:505-514 PMID: 30471397

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

FTY720 hydrochloride increased bone-marrow T-cell counts in aly/aly mice lacking lymph nodes and Peyer’s patches. This supports marrow accumulation as part of its lymphocyte-redistribution effect. The experiment did not directly establish whether altered entry or egress caused accumulation, or prove S1P1 specificity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
S1P receptor (K562, NK cells ) 0.033 nM

FTY720 (Fingolimod) Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of FTY720 (Fingolimod) from 2 published references. In vivo models include male aly/aly mice, 6–12 weeks, lacking lymph nodes and Peyer’s patches.

FTY720 (Fingolimod) In Vitro Studies

In murine splenic lymphocytes, FTY720 hydrochloride produced concentration- and exposure-dependent effects. At 1 μM, the authors reported reduced viability after 24 h but no induced apoptosis in the separate 5 h assay; higher concentrations increased apoptosis. These endpoints should not be treated as interchangeable potency measurements. [1]

Concentration- and duration-dependent splenic lymphocyte responses

Cell-based study · Splenic lymphocytes from control and aly/aly mice; shared animal section describes male aly/+ and aly/aly mice, 6–12 weeks. [1]

Viability and Annexin V apoptosis were assessed in parallel concentration-response assays with different exposure durations. Loss of viability at 24 h and increased Annexin V-positive/PI-negative cells at 5 h must not be equated. At 1 μM, the paper reports reduced 24 h viability but no induced apoptosis in the 5 h assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Splenic lymphocyte viability after 24 hReported response About 60% of control at 1 μM; very low viability at 10 μM or higher (author-reported approximations)[1]
Annexin V-positive/PI-negative cells after 5 hReported response No induced apoptosis at 1 μM; higher responses at 3–10 μM, with genotype-specific significance markings[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.03–30 μM for viability; 1–10 μM for apoptosis
Exposure duration
24 h viability exposure, followed by 3 h colorimetric reagent incubation; 5 h apoptosis exposure
Method
Culture in RPMI 1640 with 10% FCS; TetraColor One colorimetry or Annexin V/PI flow cytometry
Co-treatment
FTY720 alone; with-versus-without compound controls
Reported limits
Culture drug vehicle and its matched control are not specified in the acquired methods. Oral distilled-water vehicle is not transferred to this culture assay.
Methods and source locations

Compound reported in the paper: FTY720 (fingolimod); Compound label in the paper: FTY720 hydrochloride, synthesized

Evidence for the hydrochloride in murine splenic lymphocytes; no universal non-cytotoxic concentration or human potency inferred.

Figure 3B–D and caption, p189; Results p189; Methods cell viability/apoptosis pp187–188

Splenic lymphocyte viability after 24 h: TetraColor One; absorbance 490 nm — Figure 3B–D and caption, p189; Results p189; Methods cell viability/apoptosis pp187–188

Annexin V-positive/PI-negative cells after 5 h: Annexin V/PI flow cytometry; Figure 3C control and 3D aly/aly — Figure 3B–D and caption, p189; Results p189; Methods cell viability/apoptosis pp187–188

FTY720 (Fingolimod) In Vivo Studies

A single oral 1 mg/kg dose of FTY720 hydrochloride increased bone-marrow CD3, CD4 and CD8 T-cell counts at 24 h in aly/aly mice. This distribution study supports a mechanistic interpretation, without establishing disease-treatment efficacy. [1]

In an independent mouse study using Cayman FTY720 with salt unspecified, oral treatment produced lung S1P1 loss and pulmonary vascular leak, particularly at 5 mg/kg. Both responses were attenuated in internalization-deficient S1P1-S5A mice. This dose- and genotype-dependent adverse finding limits generalizations about receptor downregulation; it does not establish safety for the catalog material. [2]

Bone-marrow T-cell accumulation in alymphoplasia mice

Animal study · Male aly/aly mice, 6–12 weeks, lacking lymph nodes and Peyer’s patches [1]

At 24 h after a single oral FTY720 dose, bone-marrow CD3, CD4 and CD8 T-cell counts were increased compared with control. A separate THI comparator in the same design also increased these counts. Findings support marrow accumulation but do not directly track individual blood cells or distinguish increased entry from decreased egress.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Bone-marrow CD3, CD4 and CD8 T-cell countsReported response Increased to 140–190% of control values after FTY720, as reported for the subsets collectively in Results; n=3, mean ± S.E.M.[1]

Conditions shared by the study groups

Route
Oral
Frequency
Single administration
Treatment course
24 h observation
Vehicle
Distilled water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
FTY720
1 mg/kg
Control group shown in Figure 4Increased marrow CD3, CD4 and CD8 T-cell counts[1]
THI comparator
100 mg/kg
Control group shown in Figure 4Increased marrow T-cell counts; comparator response supports an S1P-gradient hypothesis[1]
FTY720
Model: Male aly/aly mice, 6–12 weeks, lacking lymph nodes and Peyer’s patches
THI comparator
Model: Male aly/aly mice, 6–12 weeks, lacking lymph nodes and Peyer’s patches
Methods and source locations

Compound reported in the paper: FTY720 (fingolimod); Compound label in the paper: FTY720 hydrochloride, synthesized

Murine lymphocyte-distribution mechanism; neither therapeutic efficacy nor direct S1P1 binding potency is established.

Figure 4 and caption, p190; Results p189; Methods reagents/flow cytometry p187; Discussion p191

Bone-marrow CD3, CD4 and CD8 T-cell counts: Flow cytometry; Student t-test; Figure 4 **p<0.01 — Figure 4 and caption, p190; Results p189; Methods reagents/flow cytometry p187; Discussion p191

FTY720 · Figure 4 and caption, p190; Results p189; Methods reagents/flow cytometry p187; Discussion p191

THI comparator · Figure 4 and caption, p190; Results p189; Methods reagents/flow cytometry p187; Discussion p191

Receptor degradation and pulmonary vascular leak in wild-type and S5A mice

Animal study · Wild-type and internalization-deficient S1P1-S5A knockin mice, 6–8 weeks; C57BL/6 mice listed in animal methods; sex not specified in the selected methods. [2]

Oral FTY720 caused dose-related loss of lung S1P1 and pulmonary dye extravasation. The S5A mutation attenuated both responses. This is evidence connecting receptor regulation to an adverse vascular endpoint, rather than a direct binding assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Lung S1P1 degradation after 24 hReported response Partial at 0.5 mg/kg and pronounced at 5 mg/kg in wild-type; attenuated in S5A mice[2]
Pulmonary vascular permeability after 24 hReported response At 5 mg/kg, approximately 6-fold above basal in wild-type (Results); attenuated in S5A mice[2]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Single administration
Treatment course
24 h
Vehicle
2% 2-hydoxypropyl-β-cyclodextran in water (source spelling)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
FTY720 0.5 mg/kg
0.5 mg/kg
Vehicle-treated animals of each genotypePartial receptor loss and measurable leak in WT at lower dose; pronounced receptor loss and greater leak at higher dose. S5A responses attenuated.[2]
FTY720 5 mg/kg
5 mg/kg
Vehicle-treated animals of each genotypePartial receptor loss and measurable leak in WT at lower dose; pronounced receptor loss and greater leak at higher dose. S5A responses attenuated.[2]
FTY720 0.5 mg/kg
Model: Wild-type and S1P1-S5A knockin mice
Reported limits: Exact salt unspecified; dye timing differs between caption and Methods.
FTY720 5 mg/kg
Model: Wild-type and S1P1-S5A knockin mice
Reported limits: Exact salt unspecified; dye timing differs between caption and Methods.
Methods and source locations

Compound reported in the paper: FTY720 (fingolimod); Compound label in the paper: FTY720, Cayman Chemical; salt not specified in paper

Parent-fingolimod literature context only; tested salt unspecified. These mouse dose-response findings do not validate an Adooq lot or predict clinical safety.

Figure 5A–B and caption; Results “FTY720 treatment at a supralymphopenic dose…”; Methods Chemicals and reagents, FTY720 treatment, In vivo vascular permeability assay, Statistics

Lung S1P1 degradation after 24 h: S1P1 immunoblot with β-actin control; Figure 5A n=3, representative experiment repeated 3 times — Figure 5A–B and caption; Results “FTY720 treatment at a supralymphopenic dose…”; Methods Chemicals and reagents, FTY720 treatment, In vivo vascular permeability assay, Statistics

Pulmonary vascular permeability after 24 h: Evans blue dye extravasation; Figure 5B caption n=17 WT and n=7 S5A; mean ± SD; not inferred as n per dose — Figure 5A–B and caption; Results “FTY720 treatment at a supralymphopenic dose…”; Methods Chemicals and reagents, FTY720 treatment, In vivo vascular permeability assay, Statistics

FTY720 0.5 mg/kg · Figure 5A–B and caption; Results “FTY720 treatment at a supralymphopenic dose…”; Methods Chemicals and reagents, FTY720 treatment, In vivo vascular permeability assay, Statistics

FTY720 5 mg/kg · Figure 5A–B and caption; Results “FTY720 treatment at a supralymphopenic dose…”; Methods Chemicals and reagents, FTY720 treatment, In vivo vascular permeability assay, Statistics

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 162359-56-0
Applications S1P Receptor antagonist
Formula C19H33NO2.HCl
Molecular Weight 343.9
Synonyms Gilenia
SMILES
CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 64 mg/mL (186.09 mM)
Water 64 mg/mL (186.09 mM)
Ethanol 64 mg/mL (186.09 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
19 mg/mL
Vehicle
Saline

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

FTY720 (Fingolimod) Research References

  1. [1] Yasuhiro Maeda, Hirotoshi Kataoka, Noriyasu Seki, et al. FTY720 induces the sequestration of circulating lymphocytes into the bone marrow in alymphoplasia mice Inflammation and Regeneration (2010). DOI: 10.2492/inflammregen.30.186 Source material
  2. [2] Myat Lin Oo, Sung-Hee Chang, Shobha Thangada, et al. Engagement of S1P1-degradative mechanisms leads to vascular leak in mice Journal of Clinical Investigation (2011). PMID: 21555855 DOI: 10.1172/JCI45403 Source material

Publications

6 publications citing this product

  1. Tina Sepasi, .et al. , Int J Pharm, 2023, Apr 5;636:122815 PMID: 36907279
  2. Tina Sepasi, .et al. , BioImpacts, 2022, 28 May PMID: 37193076
  3. Zengzi Zhou, .et al. , Infect Immun, 2020, Oct 19;88(11):e00281-20 PMID: 32868341
  4. Mayu Idehara, .et al. , Traditional & Kampo Medicine, 2020, 22 July
  5. Luwa Yuan, .et al. , Sci Rep, 2019, 9:11156 PMID: 31371790
  6. Sakai Y, .et al. , Int J Biol Macromol, 2018, Nov 22;124:505-514 PMID: 30471397

Added to your cart

View Cart Checkout
Loading...